<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82233">
  <stage>Registered</stage>
  <submitdate>24/08/2007</submitdate>
  <approvaldate>31/08/2007</approvaldate>
  <actrnumber>ACTRN12607000445471</actrnumber>
  <trial_identification>
    <studytitle>Investigation of the role of functional imaging predicting the relapse patterns of high grade gliomas</studytitle>
    <scientifictitle>A Single Group Study to Investigate the Functional Role of Imaging Using a Thallium Single Photon Emission Computed Tomography "SPECT" scan of the Brain to Predict Relapse In Patients with High Grade Gliomas</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>high grade gliomas</healthcondition>
    <healthcondition>cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Brain</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A Thallium Single Photon Emission Computed Tomography "SPECT" Scan of the Brain will be performed at 3 time points, pre treatment, 3 months post treatment and at the time of recurrence. This scan takes one hour to perform.</interventions>
    <comparator>not applicable</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>site of recurrence</outcome>
      <timepoint>brain SPECT scan performed at 3 months then followed with routine MRI's. On recurrence another SPECT scan is performed</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>survival</outcome>
      <timepoint>Patients will be followed 3 monthly till death</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>high grade gliomas (WHO III or IV)
intended treatment is for radical radiation 
available for follow up
written consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>-2147483648</inclusivemaxage>
    <inclusivemaxagetype>N/A</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>intended for palliative radiation only</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>14/09/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>25</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Thomas Eade</primarysponsorname>
    <primarysponsoraddress>Radiation Oncology
Royal North Shore Hospital
St Leonards NSW  2065</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>na</fundingname>
      <fundingaddress>na</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>NSCCAHS HREC</ethicname>
      <ethicaddress>RNSH
St Leonards NSW 2065</ethicaddress>
      <ethicapprovaldate>14/09/2006</ethicapprovaldate>
      <hrec>0607-120M</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Thomas Eade</name>
      <address>Radiation Oncology
RNSH
St Leonards NSW 2065</address>
      <phone>02 9926-5010</phone>
      <fax />
      <email>teade@nsccahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Thomas Eade</name>
      <address>Radiation Oncology
RNSH
St Leonards NSW 2065</address>
      <phone>02 9926-5010</phone>
      <fax />
      <email>teade@nsccahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Bronwyn Raymond</name>
      <address>Radiation Oncology
RNSH
St Leonards NSW 2065</address>
      <phone>02 9926-5050</phone>
      <fax>02 9926-8038</fax>
      <email>braymond@nsccahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>